As NOA-21, a neoadjuvant window-of-opportunity trial in patients with recurrent IDH1-mutant gliomas [24], INTERCEPT-H3 integrates an immune checkpoint inhibitor to amplify neoepitope-specific T cell responses. Here, IDH1 is linked to central nervous system cancer.